Methods and kits for treating cardiovascular disease

1. A method of treating a human subject at risk of a future cardiac event comprising:

(a) obtaining information regarding the human subject's single nucleotide polymorphism (SNP) alleles for each of the rs16944 polymorphic locus, the rs1143623 polymorphic locus, the rs4848306 polymorphic locus, the rs17561 polymorphic locus, and the rs1143634 polymorphic locus;

(b) determining that the subject has a positive IL-1 genotype pattern when the IL-1 genotype pattern obtained in (a) matches an IL-1 genotype pattern that is selected from the group consisting of:

(i) T/T or T/G at rs17561, C/C, T/T, C/T or T/C at rs4848306, G/G at rs1143623, C/C at rs16944 and T/T or T/C at rs1143634;

(ii) G/G at rs17561, C/C, T/T, C/T or T/C at rs4848306, G/G at rs1143623, C/C at rs16944 and C/C, T/T, C/T or T/C at rs1143634;

(iii) G/G, T/T, G/T or T/G at rs17561, C/C, T/T, C/T or T/C at rs4848306, G/G at rs1143623, C/C at rs16944 and C/C at rs1143634;

(iv) T/T or T/G at rs17561, C/C or C/T at rs4848306, G/G at rs1143623, C/T at rs16944 and T/T or T/C at rs1143634;

(v) G/G at rs17561, C/C or C/T at rs4848306, G/G at rs1143623, C/T at rs16944 and C/C, T/T, C/T or T/C at rs1143634;

(vi) G/G, T/T, G/T or T/G at rs17561, C/C or C/T at rs4848306, G/G at rs1143623, C/T at rs16944 and C/C at rs1143634;

(vii) T/T or T/G at rs17561, C/C at rs4848306, C/G at rs1143623, C/T at rs16944 and T/T or T/C at rs1143634; 2

(viii) G/G at rs17561, C/C at rs4848306, C/G at rs1143623, C/T at rs16944 and C/C, T/T, C/T or T/C at rs1143634;

(ix) G/G, T/T, G/T or T/G at rs17561, C/C at rs4848306, C/G at rs1143623, C/T at rs16944 and C/C at rs1143634;

(x) T/T or T/G at rs17561, C/C at rs4848306, G/G at rs1143623, T/T at rs16944 and T/T or T/C at rs1143634;

(xi) G/G at rs17561, C/C at rs4848306, G/G at rs1143623, T/T at rs16944 and C/C, T/T, C/T or T/C at rs1143634; and

(xii) G/G, T/T, G/T or T/G at rs17561, C/C at rs4848306, G/G at rs1143623, T/T at rs16944 and C/C at rs1143634;

(c) determining at least one of:

(i) a plasma concentration of LDL-C; and/or

(ii) a plasma concentration of Lp(a)

in a sample obtained from the subject;

(d) diagnosing the subject as at risk of a cardiac event when the subject has a positive IL-1 pattern determined in step (b) and

(i) a total LDL-C plasma concentration of at least 50 mg/dL, and/or

(ii) a total Lp(a) plasma concentration of at least 5 mg/dL; and

(e) administering APO(a)-L RX or ARC-LPA to the diagnosed subject, thereby reducing the probability of a cardiac event in the subject.

2. The method of claim 1 , further comprising administering one or more of ABT-981, AC-701, ammonium trichloro-tellurate, Anakinra, Anakinra Biosimilar, APX-200, Binimetinib, Can-04, Canakinumab, Diacerein, DLX-2681, Gevokizumab, Givinostat, Isunakinra, Rilonacept, Ron-2315, Sairei-To, SER-140, Tadekinig-alpha, Bermekimab, XL-130 or IL1 Heart Health Nutrigenomic Dietary Supplement.